As more centers begin to switch patients from reference infliximab to biosimilar options, patients who have benefitted from rapid infusions of the reference product may want to continue to receive time-saving infusions that reduce the burden of lengthy visits to infusion centers.
As more centers begin to switch patients from reference infliximab to biosimilar options, patients who have benefitted from rapid infusions of the reference product may want to continue to receive time-saving infusions that reduce the burden of lengthy visits to infusion centers.
A new study sought to evaluate the safety and outcomes of continuing rapid infusion protocols after a switch to biosimilar infliximab.
In a healthcare system that switched all eligible patients with inflammatory bowel disease (IBD) to CT-P13 (Inflectra) from the reference, all patients in the switch cohort (n = 76) who had been receiving rapid infusions of 30 minutes each were compared with a parallel cohort of patients who had received the biosimilar since initiating therapy (n = 44).
Baseline characteristics were comparable across the groups, with the exceptions of higher immunomodulator use among the maintenance cohort and a longer duration of therapy among the switch cohort. No changes were made to patients’ premedications or infusion rates. Patients were prospectively assessed for adverse events (AEs), disease activity, and drug levels.
Baseline infliximab levels before the switch were subtherapeutic in 23% of patients and supratherapeutic in 30%. During a median follow-up of 2 infliximab infusions after the switch, the investigators found no significant AEs, including infusion-related reactions, associated with rapid infusion of the biosimilar.
The authors write that rapid infusion continued through a switch to biosimilar infliximab appears to be safe and effective, and they add that switching also represents an opportunity for physicians to reassess patients’ disease activity and infliximab trough levels to inform clinical decision making.
Previous studies of rapid infusion protocols in other disease states with other biosimilars have also demonstrated that patients can continue to receive rapid infusions after a switch. A 2017 study in patients receiving rituximab showed that patients could be safely switched from the reference product to a rituximab biosimilar without reverting to slower infusion rates.
Reference
Srinivasan A, van Langenberg DR, Haar G, Milller C, Rodrigues B. Rapid 30-minute infliximab infusion protocols when switching inflammatory bowel disease (IBD) patients from originator to biosimilar infliximab. Presented at: Digestive Disease Week 2019; San Diego, CA; May 18-21, 2019. Abstract Su1847.
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
May 18th 2024A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
May 11th 2024In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.